Efficacy of Vitamin E and N-acetylcysteine in the Prevention of Contrast Induced Kidney Injury in Patients with Chronic Kidney Disease: a Double Blind, Randomized Controlled Trial
Overview
Authors
Affiliations
Background: Contrast induced acute kidney injury is one of the most frequent causes of hospital acquired acute kidney injury. The present study aims to investigate the efficacy of vitamin E or N-acetylcysteine as an adjunct to current standard therapy in the prevention of this clinical predicament. We tested the hypothesis that vitamin E or N-acetylcysteine added to standard therapy with 0.45 % saline is superior in preserving renal function in patients with chronic kidney disease stage 1-4 undergoing elective computer-assisted tomography with nonionic radiocontrast agents when compared to 0.45 % saline alone.
Design: Prospective, randomized, single-center, double-masked, double dummy, placebo-controlled, parallel clinical trial.
Methods: The patients were randomized to either vitamin E (total dose 2160 mg i.v.) or N-acetylcysteine (total dose 4800 mg p.o.) in addition to 0.45 % saline (1 mL/kg/h over 24 h) or saline alone. Serum creatinine change between baseline and 24 h after radiocontrast was the primary outcome. Contrast induced acute kidney injury was defined as a rise in serum creatinine > 25 % over the baseline value within 48 h.
Results: Thirty patients (mean age 74.6 years; 17 females; 9 diabetics; all Caucasians; mean serum creatinine 1.35 mg/dL; mean creatinine clearance 56 mL/min) were enrolled. No patient developed contrast induced acute kidney injury. There was no significant difference in serum creatinine change between the three study arms.
Conclusion: Following radiocontrast administration, neither vitamin E nor N-acetylcystein in addition to saline demonstrated an additional beneficial effect on kidney function when compared to saline alone.
Vitamin E for the Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis.
Awaji A, Bakhamees B, Alalshaikh N, Albelwi N, Al-Zahrani M, Alshammari K Cureus. 2024; 16(6):e63256.
PMID: 39070434 PMC: 11282355. DOI: 10.7759/cureus.63256.
Panova I, Tatikolov A Pharmaceuticals (Basel). 2023; 16(8).
PMID: 37630992 PMC: 10458090. DOI: 10.3390/ph16081077.
Asad A, Burton J, March D BMC Nephrol. 2020; 21(1):446.
PMID: 33097033 PMC: 7585193. DOI: 10.1186/s12882-020-02098-9.
Ahmed K, McVeigh T, Cerneviciute R, Mohamed S, Tubassam M, Karim M BMC Nephrol. 2018; 19(1):323.
PMID: 30424723 PMC: 6234687. DOI: 10.1186/s12882-018-1113-0.
Efficacy of atorvastatin on the prevention of contrast-induced acute kidney injury: a meta-analysis.
Liu L, Liu Y, Wu M, Sun Y, Ma F Drug Des Devel Ther. 2018; 12:437-444.
PMID: 29535505 PMC: 5840281. DOI: 10.2147/DDDT.S149106.